Last reviewed · How we verify
Losartan Tablets & QingReMoShen Granule — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Losartan Tablets & QingReMoShen Granule (Losartan Tablets & QingReMoShen Granule) — wanglin.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Losartan Tablets & QingReMoShen Granule TARGET | Losartan Tablets & QingReMoShen Granule | wanglin | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Losartan Tablets & QingReMoShen Granule CI watch — RSS
- Losartan Tablets & QingReMoShen Granule CI watch — Atom
- Losartan Tablets & QingReMoShen Granule CI watch — JSON
- Losartan Tablets & QingReMoShen Granule alone — RSS
Cite this brief
Drug Landscape (2026). Losartan Tablets & QingReMoShen Granule — Competitive Intelligence Brief. https://druglandscape.com/ci/losartan-tablets-qingremoshen-granule. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab